Bernard Fox

Bernard A. Fox, PhD, is an internationally recognized leader in immuno-oncology and the Co-Founder, President, and CEO of UbiVac, a clinical stage immuno-oncology company.1 He has held this position at UbiVac since 2005, focusing on the research, development, and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases.1

Professional Background

Dr. Fox has an extensive background in cancer research and immunotherapy:

Academic Positions::

• Harder Family Endowed Chair for Cancer Research at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center (1994-present)1
• Guest Professor at Xian Jiaotung University, China (1999-2008)1
• Guest Professor at Ludwig-Maximilians-University, Department of Surgery (2001-2002)1

Research Experience::

• Senior Staff Fellow and Staff Fellow at the National Cancer Institute (1985-1990)1
• Surgical Oncology at the University of Michigan Medical School (1990-1994)1

Leadership Roles

Dr. Fox has held several leadership positions in professional organizations:

• Chair of the World Immunotherapy Council (2012-present)1
• Ambassador for the Society for Immunotherapy of Cancer (SITC) (2012-present)1
• Vice President of the International Society for Biological Therapy of Cancer (iSBTc, now SITC) (2006-2008)1

Education

• PhD in Regulatory Cell Biology and Biophysics from Wayne State University (1979-1985)1
• MS in Immunology from the University of Detroit Mercy (1975-1978)1
• Staff Fellow in Cancer Immunotherapy at the National Cancer Institute, NIH (1985-1990)1

Recent Achievements

In 2024, Dr. Fox was honored with a Society for Immunotherapy of Cancer Lifetime Achievement Award, recognizing his significant contributions to the field of cancer immunotherapy.3

Bernard A. Fox continues to be actively involved in cancer research and immunotherapy development, regularly participating in international conferences and discussions on breakthroughs in cancer immunotherapy.2